Drugs News and Research

RSS

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013.

4 Mar 2014

A-PARADDISE consortium obtains funds to develop innovative therapies for neglected parasitic diseases

The international consortium A-PARADDISE (Anti-Parasitic Drug Discovery in Epigenetics), coordinated by Inserm, has just obtained funds of €6 million from the European Commission to conduct large-scale testing of innovative therapies against four neglected parasitic diseases: schistosomiasis, leishmaniasis, Chagas disease and malaria.

4 Mar 2014

Nanomedicine – Past, Present and Future

News-Medical speaks to Frank Boehm about the fundamentals of nanomedicine and the nanotechnologies of the future.

4 Mar 2014

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.

4 Mar 2014

Drug that unleashes immune system can produce lasting remissions in patients with melanoma

A drug that unleashes the immune system to attack cancer can produce lasting remissions and hold the disease in check - for more than two years, in some cases - in many patients with advanced melanoma, according to a new study by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, and allied institutions.

4 Mar 2014

Medical student receives award for finding out drugs to treat peripheral vascular disease

Working at a Saint Louis University laboratory, second-year medical student Weston Gordon performed several studies investigating two novel drug therapies that may be useful in the treatment of peripheral vascular disease in patients with Type 2 diabetes.

4 Mar 2014

New report explains how pathogens exploit immune systems to evade bodies' defenses

A new report appearing in the March 2014 issue of The FASEB Journal helps shed light on what drives the evolution of pathogens, as well as how our bodies adapt to ward them off.

4 Mar 2014

Researchers identify drug using yeast model that reduces levels of toxic protein in brains of AD patients

Using a yeast model of Alzheimer's disease (AD), Whitehead Institute researchers have identified a drug that reduces levels of the toxic protein fragment amyloid-β (Aβ) and prevents at least some of the cellular damage caused when Aβ accumulates in the brains of AD patients.

4 Mar 2014

Protamine antidote can be effective in reversing low-molecular-weight heparin

Low-molecular-weight heparin is commonly used in surgeries to prevent dangerous blood clots. But when patients experience the other extreme - uncontrolled bleeding - in response to low-molecular-weight heparin, there is no antidote.

4 Mar 2014

New study shows increase in certain macrophages may lead to therapeutic targets for Crohn's disease

For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.

4 Mar 2014

Novel scaffold protein regulates mu opioid receptor induced signaling activation

Researchers found initial confirmation that a novel scaffold protein previously unassociated with the mu opioid receptor (MOR) regulates MOR-induced signaling activation.

4 Mar 2014

Blocking Netrin-1 in immune system stops chronic inflammation and insulin resistance tied to obesity

Researchers at NYU Langone Medical Center have found that blocking the action of a key signaling molecule in the immune system known as Netrin-1 stalls chronic inflammation and insulin resistance tied to obesity and often derived from fatty diets.

4 Mar 2014

Research provides insight into biologic mechanisms that individual cancer cells use to metastasize to brain

New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.

4 Mar 2014

Viewpoints: Frightening seniors; regulating e-cigarettes; waiting for black lung drugs

The Obama administration's proposed cuts to Medicare Advantage plans - the private insurance plans that cover almost 30 percent of all Medicare beneficiaries - are fair and reasonable. As it happens, they are also mandated by law. Yet Republicans, sensing a campaign issue, are telling older and disabled Americans that the administration is "raiding Medicare Advantage to pay for Obamacare." The health insurance industry, for its part, is warning that enrollees will suffer higher premiums, lower benefits and fewer choices among doctors if the cuts go into force (3/1).

4 Mar 2014

Study finds significant reduction in hospital admissions with Medicare Part D prescription coverage

A new study by the Johns Hopkins Bloomberg School of Public Health and the University of Illinois at Chicago finds that Medicare Part D prescription coverage significantly reduced hospital admissions and program expenditures totaling $1.5 billion annually.

4 Mar 2014

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

The first detailed results from AbbVie's pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4.

4 Mar 2014

Angry outbursts increase heart attack risk

Call it what you will - getting red in the face, hot under the collar, losing your cool, blowing your top - we all experience anger. And while we know that anger is a normal, sometimes even beneficial emotion, we're also aware of the often harmful connection between anger and health. New research from Beth Israel Deaconess Medical shows an even more compelling reason to think about getting anger in check - a nearly fivefold increase in risk for heart attack in the two hours following outbursts of anger.

4 Mar 2014

New research uncovers abnormal molecular signaling pathways for kidney failure

Prevention and reversal of chronic kidney disease is an urgent public health need. The disease affects 1 in 10 Americans, is debilitating and deadly, and existing drugs, at best, offer only mild delay in progression to end-stage kidney failure.

4 Mar 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.

4 Mar 2014

Drugs News and Research

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

A-PARADDISE consortium obtains funds to develop innovative therapies for neglected parasitic diseases

Nanomedicine – Past, Present and Future

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Drug that unleashes immune system can produce lasting remissions in patients with melanoma

Medical student receives award for finding out drugs to treat peripheral vascular disease

New report explains how pathogens exploit immune systems to evade bodies' defenses

Researchers identify drug using yeast model that reduces levels of toxic protein in brains of AD patients

Protamine antidote can be effective in reversing low-molecular-weight heparin

New study shows increase in certain macrophages may lead to therapeutic targets for Crohn's disease

Novel scaffold protein regulates mu opioid receptor induced signaling activation

Blocking Netrin-1 in immune system stops chronic inflammation and insulin resistance tied to obesity

Research provides insight into biologic mechanisms that individual cancer cells use to metastasize to brain

Viewpoints: Frightening seniors; regulating e-cigarettes; waiting for black lung drugs

Study finds significant reduction in hospital admissions with Medicare Part D prescription coverage

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

Angry outbursts increase heart attack risk

New research uncovers abnormal molecular signaling pathways for kidney failure

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News